Diffuse Large B-Cell Lymphoma
GO44145
A Phase III, Multicenter, Randomized, Open‑Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination with Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (POLA-R-CHP) Versus POLA‑R‑CHP in Previously Untreated Patients with Large B-Cell Lymphoma
